methyl (6S)-2'-oxo-1'-{[2-(trimethylsilyl)ethoxy]methyl}-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylate | 1375542-65-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: methyl (6S)-2'-oxo-1'-{[2-(trimethylsilyl)ethoxy]methyl}-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylate
• 英文别名: Methyl(6S)-2'-oxo-1'-{[2-(trimethylsilyl)ethoxy]methyl}-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylate；methyl (6S)-2'-oxo-1'-(2-trimethylsilylethoxymethyl)spiro[5,7-dihydrocyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylate
• CAS: 1375542-65-6
• 化学式: C₂₂H₂₇N₃O₄Si
• 分子量: 425.56
• InChiKey: AHBTVHMJLZZFQM-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.96
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  81.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl (6S)-2'-oxo-1'-{[2-(trimethylsilyl)ethoxy]methyl}-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylate 在 盐酸 作用下， 以 甲醇 为溶剂， 生成 methyl (S)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylate
  参考文献：
  名称：

  Ubrogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Treatment of migraine

  摘要：

  Migraineis ranked as the sixth cause of years lost due to disability, with around 1.04 billion migraine sufferers globally. Triptans are considered the standard for acute migraine treatment, but an important number of migraineurs do not respond to them and these drugs are contraindicated in patients with cardiovascular disease. Migraine therapy is currently undergoing tremendous development, i.e., 5-HT1F receptor agonists (ditans), anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies, and small-molecule CGRP receptor antagonists (gepants). Ubrogepant (MK-1620) is a small-molecule, potent and selective CGRP receptor antagonist. In two phase III clinical trials (ACHIEVE I and II), ubrogepant showed, at 2 hours, significant percentages of pain freedom, and absence of the most bothersome symptoms in migraine patients. In a phase III study to assess the long-term (52-week) safety and tolerability, ubrogepant displayed good tolerability, and no signs of hepatic toxicity. In March 2019, the U.S. Food and Drug Administration accepted the new drug application (NDA) for ubrogepant for the acute treatment of migraine.

  DOI：

  10.1358/dof.2019.44.11.3035581
• 作为产物：
  描述：

  5-溴-吡啶-2,3-二甲酸二甲酯 在 sodium tetrahydroborate 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 乙醇 、 sodium acetate 、 caesium carbonate 、 三乙胺 、 calcium chloride 作用下， 以 四氢呋喃 、 乙醇 、 二甲胺 为溶剂， 85.0 ℃ 、2.07 MPa 条件下， 反应 95.0h， 生成 methyl (6S)-2'-oxo-1'-{[2-(trimethylsilyl)ethoxy]methyl}-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylate
  参考文献：
  名称：

  [EN] PYRIDINE CGRP RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DE RÉCEPTEUR DE CGRP À BASE DE PYRIDINE

  摘要：

  本发明涉及吡啶衍生物，其为CGRP受体拮抗剂，在治疗或预防涉及CGRP的疾病，如偏头痛等方面有用。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及CGRP的这类疾病中使用这些化合物和组合物。

  公开号：

  WO2013169563A1

文献信息

• PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS
  申请人：Bell Ian M.

  公开号：US20120122899A1

  公开（公告）日：2012-05-17

  The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及哌啶酮羧酰胺吖啶衍生物，它们是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗CGRP参与的这类疾病中使用这些化合物和组合物。
• 哌啶酮羧酰胺氮杂茚满CGRP受体拮抗剂
  申请人：默沙东公司

  公开号：CN103328478A

  公开（公告）日：2013-09-25

  本发明涉及式I的哌啶酮羧酰胺氮杂茚满衍生物，其是CGRP受体的拮抗剂，并可用于治疗或预防其中涉及CGRP的疾病，诸如偏头痛。本发明还涉及含有这些化合物的药物组合物和这些化合物与组合物在预防或治疗其中涉及CGRP的这样的疾病中的用途。
• Piperidinone carboxamide azaindane CGRP receptor antagonists
  申请人：Bell Ian M.

  公开号：US08481556B2

  公开（公告）日：2013-07-09

  The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及对CGRP受体具有拮抗作用的哌啶酮羧酰胺唑吖啶衍生物，可用于治疗或预防涉及CGRP的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及CGRP的疾病中使用这些化合物和组合物。
• PYRIDINE CGRP RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150099771A1

  公开（公告）日：2015-04-09

  The present invention is directed to pyridine derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及吡啶衍生物，其为CGRP受体拮抗剂，可用于治疗或预防涉及CGRP的疾病，例如偏头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗涉及CGRP的这些疾病的方法。
• Pyridine CGRP receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US09227973B2

  公开（公告）日：2016-01-05

  The present invention is directed to pyridine derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及吡啶衍生物，其为CGRP受体拮抗剂，可用于治疗或预防涉及CGRP的疾病，例如偏头痛。该发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及CGRP的这些疾病中使用这些化合物和组合物的用途。